Patents by Inventor Daniel Scherman
Daniel Scherman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11492621Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c. 2991+1655 A>G CEP290 mRNA.Type: GrantFiled: March 3, 2020Date of Patent: November 8, 2022Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—CHIMIE PARISTECH—ECOLE NATIONALE SUPERIEURE DE CHIME DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
-
Patent number: 11291630Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.Type: GrantFiled: September 16, 2016Date of Patent: April 5, 2022Inventors: Nathalie Mignet, Vincent Pierre-Marie Boudy, Johanne Seguin, Daniel Scherman, Yoran Beldengrun
-
Publication number: 20200368373Abstract: The present invention relates to an optical imaging agent of formula (SIGNAL)n-SUPPORT-(L-BIOVECTOR)m, wherein: SUPPORT represents a physiologically acceptable chemical or biological substrate, with a particle size of between 1 and 100 nm, SIGNAL is a fluorophore, L is a linker of formula —C(X)—R1—Y—, with X being O, NH or S R1 being a (C1-C6)alkyl group, optionally R1 being a (C1-C6)alkyl group, optionally interrupted by 1 to 3 groups selected from —O—, —NH—, —C(O)—, —NHC(O)—, —(O)CNH—, —C(O)NH—N?C—, —N?C—, and (I), Y being NH or a —(O)CNH— group, and BIOVECTOR is a carbohydrate targeting markers of inflammation, advantageously selected from the group consisting of mannose, sialyl LewisX and derivatives thereof, n is greater than or equal to 0.5 and is less than 2, m is between 0 and 30, preferably between 1 and 30, more preferably between 5 and 20, diagnostic compositions comprising same and use thereof as a diagnostic agent (in vivo or ex vivo), or as contrast agent for image-guided surgery.Type: ApplicationFiled: February 21, 2019Publication date: November 26, 2020Inventors: Yongmin ZHANG, Michel BESSODES, Johanne SEGUIN, Nathalie MIGNET, Daniel SCHERMAN
-
Publication number: 20200291402Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c. 2991+1655 A>G CEP290 mRNA.Type: ApplicationFiled: March 3, 2020Publication date: September 17, 2020Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
-
Patent number: 10597654Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2991+1655 A>G CEP290 mRNA.Type: GrantFiled: August 31, 2017Date of Patent: March 24, 2020Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—CHIMIE PARIS TECH—ECOLE NATIONALE SUPERIEURE DE DE CHIME DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
-
Publication number: 20190192430Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.Type: ApplicationFiled: September 16, 2016Publication date: June 27, 2019Applicants: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique-Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Nathalie Mignet, Vincent Pierre-Marie Boudy, Johanne Seguin, Daniel Scherman, Yoran Beldengrun
-
Patent number: 9877653Abstract: Multimodal optical and magnetic resonance imaging methods based on the use of persistent luminescence nanoparticles. Use of mesoporous persistent luminescence <<core-shell>> complexes for theranostic applications.Type: GrantFiled: January 30, 2013Date of Patent: January 30, 2018Assignee: Centre National de la Recherche Scientifique (CNRS)Inventors: Thomas Maldiney, Cyrille Richard, Daniel Scherman, Didier Gourier, Bruno Viana, Aurelie Bessiere
-
Publication number: 20180016579Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.Type: ApplicationFiled: August 31, 2017Publication date: January 18, 2018Applicants: INSERM (Institut National de la Sante et de la Rec herche Medicale), CNRS (Centre National de la Recherche Scientifique ), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP - Chimie ParisTech - Ecole Nationale Superie ure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARISInventors: Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
-
Patent number: 9783547Abstract: The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R1, R2, R3, R4 and Ar are as defined in claim 1, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a composition comprising said analogs, their use as medicament, in particular for the treatment of cancer, and a process for their preparation.Type: GrantFiled: January 15, 2015Date of Patent: October 10, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARISInventors: Guy Chabot, Sylviane Giorgi-Renault, Stéphanie Desbene-Finck, Philippe Helissey, Raphaël Labruere, Marlène Testud, Daniel Scherman
-
Patent number: 9777272Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.Type: GrantFiled: September 16, 2016Date of Patent: October 3, 2017Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—Chimie ParisTech—Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARISInventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
-
Patent number: 9572776Abstract: The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy.Type: GrantFiled: January 20, 2010Date of Patent: February 21, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Virginie Escriou, Pascal Bigey, Daniel Scherman
-
Publication number: 20170044533Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.Type: ApplicationFiled: September 16, 2016Publication date: February 16, 2017Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP - Chimie ParisTech - Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARISInventors: Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
-
Patent number: 9540425Abstract: The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.Type: GrantFiled: July 29, 2011Date of Patent: January 10, 2017Assignee: INSTITUT DE RECHERCHE POUR LE DéVELOPPEMENT (IRD)Inventors: Nicaise Tuikue Ndam, Philippe Deloron, Sedami Ursula Alix Carine Gnidéhou, Mickaël Quiviger, Pascal Bigey, Daniel Scherman
-
Publication number: 20160333022Abstract: The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R1, R2, R3, R4 and Ar are as defined in claim 1, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a composition comprising said analogs, their use as medicament, in particular for the treatment of cancer, and a process for their preparation.Type: ApplicationFiled: January 15, 2015Publication date: November 17, 2016Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M EDICALE (INSERM), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARISInventors: Guy CHABOT, Sylviane GIORGI-RENAULT, Stéphanie DESBENE-FINCK, Philippe HELISSEY, Raphaël LABRUERE, Marléne TESTUD, Daniel SCHERMAN
-
Patent number: 9487782Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.Type: GrantFiled: November 18, 2014Date of Patent: November 8, 2016Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—Chimie ParisTech—Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARISInventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
-
Patent number: 9474782Abstract: The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies.Type: GrantFiled: March 4, 2013Date of Patent: October 25, 2016Assignee: Association Francaise contre les MyopathiesInventors: Antoine Kichler, Daniel Scherman
-
Patent number: 9175055Abstract: The invention relates to the use of fibromodulin and lumican, particularly active fragments thereof, to increase muscle mass, especially in the treatment of muscular dystrophies.Type: GrantFiled: October 15, 2012Date of Patent: November 3, 2015Assignee: ASSOCIATION FRANCAISE CONTRE LES MYOPATHIESInventors: Antoine Kichler, Daniel Scherman
-
Publication number: 20150111951Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.Type: ApplicationFiled: November 18, 2014Publication date: April 23, 2015Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), Genethon, Universite Paris Descartes, ENSCP - Chimie ParisTech - Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, Assistance Publique Hopitaux De ParisInventors: Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
-
Patent number: 9012425Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.Type: GrantFiled: June 8, 2012Date of Patent: April 21, 2015Assignees: INSERM (Institute National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), Genethon, Universite Paris Descartes, ENSCP—Chimie Paris Tech—Ecole National Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, Assistance Publique—Hopitaux de ParisInventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
-
Publication number: 20140371575Abstract: Multimodal optical and magnetic resonance imaging methods based on the use of persistent luminescence nanoparticles. Use of mesoporous persistent luminescence <<core-shell>> complexes for theranostic applications.Type: ApplicationFiled: January 30, 2013Publication date: December 18, 2014Inventors: Thomas Maldiney, Cyrille Richard, Daniel Scherman, Didier Gourier, Bruno Viana, Aurelie Bessiere